Literature DB >> 9210472

Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells.

C A Riddick1, W L Ring, J R Baker, C R Hodulik, T D Bigby.   

Abstract

The aim of this study was to assess the effect of dexamethasone on 5-lipoxygenase pathway expression in human peripheral blood monocytes and the acute monocytic leukemia cell line, THP-1. Cells were conditioned over a period of days with dexamethasone, at concentrations relevant in vivo, to study the effect of the glucocorticoid on calcium-ionophore-stimulated 5-lipoxygenase product and arachidonic acid release. The effect of dexamethasone on levels of immunoreactive protein and steady-state messenger RNA encoding for 5-lipoxygenase and its activating protein (5-LAP) was also assessed. Dexamethasone increased the stimulated release of 5-lipoxygenase products from both monocytes and THP-1 cells in a dose-dependent fashion. The increase in product generation was not due to changes in the availability of arachidonic acid. However, immunoreactive protein and steady-state messenger RNA encoding for 5-lipoxygenase and 5-LAP were increased by conditioning with dexamethasone. There was no apparent effect of the glucocorticoid on LTA4-hydrolase-immunoreactive protein levels or specific activity. We conclude that dexamethasone increases 5-lipoxygenase pathway expression in both monocytes and in THP-1 cells. This effect is due, at least in part, to increases in immunoreactive protein and steady-state messenger RNA encoding for 5-lipoxygenase and 5-LAP. These results suggest a role for glucocorticoids in the regulation of 5-lipoxygenase pathway expression in mononuclear phagocytes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9210472     DOI: 10.1111/j.1432-1033.1997.00112.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  17 in total

Review 1.  Regulation of expression of the 5-lipoxygenase pathway.

Authors:  T D Bigby
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Pharmacology and safety of the leukotriene antagonists.

Authors:  L J Smith
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

3.  Lipoxins and other arachidonate derived mediators in bronchial asthma.

Authors:  C Chavis; I Vachier; P Godard; J Bousquet; P Chanez
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 4.  An inflammatory review of glucocorticoid actions in the CNS.

Authors:  Shawn F Sorrells; Robert M Sapolsky
Journal:  Brain Behav Immun       Date:  2006-12-27       Impact factor: 7.217

Review 5.  Montelukast: a review of its therapeutic potential in persistent asthma.

Authors:  B Jarvis; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

6.  Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients.

Authors:  C G Löfdahl; T F Reiss; J A Leff; E Israel; M J Noonan; A F Finn; B C Seidenberg; T Capizzi; S Kundu; P Godard
Journal:  BMJ       Date:  1999-07-10

7.  5-Lipoxygenase inhibitors induce potent anti-proliferative and cytotoxic effects in human tumour cells independently of suppression of 5-lipoxygenase activity.

Authors:  A S Fischer; J Metzner; S D Steinbrink; S Ulrich; C Angioni; G Geisslinger; D Steinhilber; T J Maier
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

8.  Effect of intravenous corticosteroid on ex vivo leukotriene generation by blood leucocytes of normal and asthmatic patients.

Authors:  P P Hood; T P Cotter; J F Costello; A P Sampson
Journal:  Thorax       Date:  1999-12       Impact factor: 9.139

Review 9.  Lysophospholipid acyltransferases and leukotriene biosynthesis: intersection of the Lands cycle and the arachidonate PI cycle.

Authors:  Robert C Murphy; Giancarlo Folco
Journal:  J Lipid Res       Date:  2019-01-03       Impact factor: 5.922

10.  Expression of 5-lipoxygenase and 15-lipoxygenase in rheumatoid arthritis synovium and effects of intraarticular glucocorticoids.

Authors:  Karina Roxana Gheorghe; Marina Korotkova; Anca Irinel Catrina; Linda Backman; Erik af Klint; Hans-Erik Claesson; Olof Rådmark; Per-Johan Jakobsson
Journal:  Arthritis Res Ther       Date:  2009-06-04       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.